Arbutus Biopharma Corp (ABUS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ABUS currently has 195M outstanding shares. with limited dilution risk as only 18.9M additional shares (9.7%) are authorized for issuance. The company has minimally diluted shareholders by 5.94% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 13, 2026 |
10-Q filing | 195.2M shares outstanding |
200M | 19M |
| Mar 23, 2026 |
10-K filing | 191.6M shares outstanding |
190M | 22M |
| Nov 13, 2025 |
10-Q filing | 191.8M shares outstanding |
190M | 22M |
| May 14, 2025 |
10-Q filing | 190.7M shares outstanding |
190M | 23M |
| Mar 27, 2025 |
10-K filing | 185.6M shares outstanding |
190M | 28M |
| Nov 06, 2024 |
10-Q filing | 189.0M shares outstanding |
190M | 25M |
| Nov 06, 2024 |
S-3 filing: The company may offer common shares, preferred shares, warrants, debt securities, or units up to an aggregate initial offering price of $300,000,000. |
190M | 25M |
| Aug 08, 2024 |
10-Q filing | 188.0M shares outstanding |
190M | 210K |
| May 02, 2024 |
10-Q filing | 175.6M shares outstanding |
180M | 13M |
| Mar 05, 2024 |
10-K filing | 166.0M shares outstanding |
170M | 22M |
| Nov 07, 2023 |
10-Q filing | 167.5M shares outstanding |
170M | 21M |
| Aug 03, 2023 |
10-Q filing | 166.1M shares outstanding |
170M | 22M |
| May 04, 2023 |
10-Q filing | 161.6M shares outstanding |
160M | 27M |
| Mar 02, 2023 |
10-K filing | 150.9M shares outstanding |
150M | 37M |
| Nov 09, 2022 |
10-Q filing | 151.0M shares outstanding |
150M | 37M |
| Aug 04, 2022 |
10-Q filing | 148.8M shares outstanding |
150M | 39M |
| May 05, 2022 |
10-Q filing | 148.4M shares outstanding |
150M | 40M |
| Mar 03, 2022 |
10-K filing | 148.6M shares outstanding |
150M | 40M |
| Dec 13, 2021 |
8-K filing: Arbutus Biopharma Corporation entered into an Exclusive License Agreement with Qilu Pharmaceutical Co., Ltd. and a Share Purchase Agreement with Anchor Life Limited, an affiliate of Qilu Pharmaceutical, for the sale of 3,579,952 common shares at $4.19 per share, resulting in gross proceeds of $15.0 million. ($15.0M proceeds) |
140M | 53M |
| Nov 04, 2021 |
S-3 filing: Arbutus Biopharma Corporation files an S-3 registration statement for the potential offering of common shares, preferred shares, warrants, debt securities, or units up to an aggregate initial offering price of $250,000,000, as well as the potential resale of up to 38,847,462 common shares by a selling shareholder. |
97M | 91M |
| Nov 04, 2021 |
10-Q filing | 135.3M shares outstanding |
140M | 53M |
| Oct 08, 2021 |
8-K filing: Arbutus Biopharma Corporation is offering up to $75.0 million of its common shares under a prospectus supplement and has sold an aggregate of 11,869,217 common shares for net proceeds of approximately $44.9 million during the three months ended September 30, 2021. ($44.9M proceeds) |
97M | 53M |
| Aug 05, 2021 |
10-Q filing | 96.9M shares outstanding |
97M | 53M |
| May 05, 2021 |
10-Q filing | 93.4M shares outstanding |
93M | 56M |
| Mar 04, 2021 |
10-K filing | 95.6M shares outstanding |
96M | 54M |
| Nov 05, 2020 |
10-Q filing | 84.9M shares outstanding |
85M | 64M |
| Aug 28, 2020 |
S-3 filing: Arbutus Biopharma Corporation files an S-3 registration statement to register an indeterminate number of common shares, preferred shares, warrants to purchase common shares, preferred shares or debt securities, such indeterminate principal amount of debt securities and a combination of such securities, separately or as units, as may be sold by the registrant from time to time, which collectively shall have an aggregate initial offering price not to exceed $200,000,000. |
81M | 68M |
| Aug 07, 2020 |
10-Q filing | 80.9M shares outstanding |
81M | 0 |
| May 11, 2020 |
10-Q filing | 69.0M shares outstanding |
69M | 0 |
| Mar 05, 2020 |
10-K filing | 68.9M shares outstanding |
69M | 0 |